Protection against fetal infection with either bovine viral diarrhea virus type 1 or type 2 using a noncytopathic type 1 modified-live virus vaccine.
Two bovine viral diarrhea virus (BVDV) fetal protection studies were done using a monovalent noncytopathic (NCP) BVDV vaccine containing type 1 BVDV. In study 1, thirty-two fetuses (23 vaccinates and nine controls) were recovered following fetal challenge with the type 1a BJ strain. Twenty of twenty-three fetuses from the vaccinates were negative for BVDV type 1 while all of the controls (nine of nine) were infected. In study 2, twenty-two animals (14 vaccinates and eight controls) were challenged with the type 2 PA131 strain. Thirteen of the fourteen fetuses from the vaccinates were negative for BVDV type 2 while all of the nonvaccinated controls (eight of eight) were infected. These results indicate the efficacy of a monovalent NCP BVDV vaccine in providing excellent protection against either BVDV type 1 or 2 fetal infection.
Brock
K V
KV
Department of Pathobiology, College of Veterinary Medicine, Auburn University, Auburn, AL 36849, USA.
McCarty
K
K
Chase
C C L
CC
Harland
R
R
D000818:Animals; D000914:Antibodies, Viral / Q000032:analysis; D001912:Bovine Virus Diarrhea-Mucosal Disease / Q000517:prevention & control* / Q000635:transmission; D002417:Cattle; D030241:Diarrhea Virus 1, Bovine Viral / Q000276:immunology* / Q000302:isolation & purification; D030242:Diarrhea Virus 2, Bovine Viral / Q000276:immunology* / Q000302:isolation & purification; D005260:Female; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control / Q000662:veterinary*; D011247:Pregnancy; D016896:Treatment Outcome; D014611:Vaccination / Q000662:veterinary*; D014613:Vaccines, Attenuated; D014765:Viral Vaccines / Q000627:therapeutic use*
D000914:Antibodies, Viral; D014613:Vaccines, Attenuated; D014765:Viral Vaccines